A brief history of anti-VEGF for the treatment of ocular angiogenesis
- PMID: 22749677
- PMCID: PMC5691342
- DOI: 10.1016/j.ajpath.2012.06.006
A brief history of anti-VEGF for the treatment of ocular angiogenesis
Abstract
In 1994, The American Journal of Pathology published a key article reporting that hypoxic retina produces vascular endothelial growth factor (VEGF), suggesting a role for VEGF in ocular neovascularization. Subsequent developments in anti-VEGF treatment for neovascular eye disease have improved visual outcomes and changed the standard of care in retinal medicine and ophthalmology.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
References
-
- Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–1186. - PubMed
-
- Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–1309. - PubMed
-
- Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., Connolly D.T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246:1309–1312. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
